The Evaluation of the Factors Affecting Mortality in Cases of HIV-infected Pneumocystis Jiroveci Pneumonia
Klimik Dergisi/Klimik Journal · 2021
DOI: 10.36519/kd.2021.3164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klimik Dergisi/Klimik Journal, 2021. Verfasst von Ayşe İnci und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective
Pneumocystis jiroveci pneumonia (PJP) is a common opportunistic infection in human immunodeficiency virus (HIV) infection cases. This study aimed to investigate the mortality rate and the factors affecting mortality in HIV-infected PJP cases followed in our clinic.
Methods
In this study HIV (+) cases followed up in our clinic between 2012-2019 were included. Age, sex, comorbidity status, LDH, CD4, lymphocyte, albumin, values, and blood gas results of these patients were recorded at the time of diagnosis.
Results
Twenty-eight patients with the diagnosis of HIV-infected PJP were included in the study. The mean age of the patients was 45.7 years, and the male ratio was 78.6% (18/28). The overall hospital mortality rate was 35.7% (10/28) among the cases.
Conclusions
As a result, performing studies involving many patients may be beneficial in these patients for diagnosis, follow-up and early treatment.
Zitieren
APA
İnci, A., Konyalı, A. R., & Sarı, N. D. (2021). The Evaluation of the Factors Affecting Mortality in Cases of HIV-infected Pneumocystis Jiroveci Pneumonia. Klimik Dergisi/Klimik Journal. https://doi.org/10.36519/kd.2021.3164
Vancouver
İnci A, Konyalı AR, Sarı ND. The Evaluation of the Factors Affecting Mortality in Cases of HIV-infected Pneumocystis Jiroveci Pneumonia. Klimik Dergisi/Klimik Journal. 2021. doi:10.36519/kd.2021.3164
BibTeX
@article{nci2021,
author = {İnci, Ayşe and Konyalı, Ahmet Refik and Sarı, Nagehan Didem},
title = {The Evaluation of the Factors Affecting Mortality in Cases of HIV-infected Pneumocystis Jiroveci Pneumonia},
journal = {Klimik Dergisi/Klimik Journal},
year = {2021},
doi = {10.36519/kd.2021.3164}
}
EUVIMED